Lipovast

Atorvastatin, the active ingredient in Lipovast, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol and is used in patients with hypercholesterolemia and related cardiovascular risk.

GNH USA supplies Lipovast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is a statin that targets lipid metabolism disorders.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Mixed dyslipidemia: improves overall lipid profile by lowering triglycerides and raising HDL‑cholesterol. Primary prevention of cardiovascular disease: decreases the risk of myocardial infarction, stroke and cardiovascular death. Secondary prevention of cardiovascular disease: reduces recurrence of cardiovascular events in patients with established disease.

Common Side Effects: - Muscle aches or weakness - Elevated liver enzymes (ALT, AST) - Gastrointestinal discomfort such as nausea or abdominal pain - Headache

Serious or Rare Side Effects: - Rhabdomyolysis, a severe muscle breakdown that can lead to renal failure - Acute liver injury, presenting with jaundice or severe enzyme elevation - Allergic reactions, including rash, pruritus, angioedema or anaphylaxis

When prescribing Lipovast, clinicians should consider several safety measures.

Monitor liver function: baseline and periodic liver enzyme testing is recommended. Assess muscle symptoms: discontinue if unexplained muscle pain occurs with elevated creatine kinase. Avoid in pregnancy: contraindicated due to fetal risk (Category X). Use caution in renal impairment: dose adjustment may be required. Drug interactions: review concomitant medications for CYP3A4 inhibitors. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Atorvastatin may interact with a range of medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase atorvastatin exposure. - Grapefruit juice: may raise plasma concentrations and risk of toxicity. - Cyclosporine: enhances risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may potentiate anticoagulant effect, requiring INR monitoring. - Antidiabetic agents: may necessitate adjustment of glucose‑lowering therapy. - Niacin: combined use can increase the likelihood of muscle toxicity.